Page 3 - Restricted Use News Today

Indias drug controller grants approval to 1st intranasal COVID-19 vaccine-

Hyderabad based biotechnology company Bharat Biotech has launched the world's first nasal Covid-19 vaccine. According to a Tweet shared by Bharat Biotech, iNCOVACC recently received approval under Restricted Use in Emergency Situation for ages 18 and above for heterologous booster doses According to Bharat Biotech, iNCOVACC is a novel adenovirus vectored, intranasal vaccine for COVID-19.…

The nasal delivery system has been designed and developed to be cost-effective in low- and middle-income countries, Bharat Biotech said.

Makers of the world’s first intranasal Covid 19 shot, Hyderabad-based Bharat Biotech, on Monday announced that the vaccine iNCOVACC (BBV154) had received approval from the Central Drugs Standard Control Organisation (CDSCO) under Restricted Use in Emergency Situation for ages 18 and above, in

Leading vaccine maker, Bharat Biotech International Limited (BBIL) on Monday announced that world's first intranasal vaccine for Covid-19, iNCOVACC (BBV154), has received approval from the Central Drugs Standard Control Organisation (CDSCO) ...

Get latest articles and stories on India at LatestLY. iNCOVACC, on Tuesday, became the worlds first intra-nasal vaccine to receive both Primary series and Heterologous booster approval, Bharat Biotech International Limited (BBIL) announced India News | India-made INCOVACC, Worlds First Intra-nasal Vaccine to Receive Approval for Both Primary Series, Heterologous Booster.

INCOVACC, on Tuesday, became the worlds first intra-nasal vaccine to receive both Primary series and Heterologous booster approval, Bharat Biotech International Limited (BBIL) announced in a press release.

For individuals 18 years of age and older, the DCGI has authorised the use of Bharat Biotechs five arms heterologous booster, ANI reported.

The Subject Expert Committee (SEC) members of the Drugs Controller General of India (DCGI) are going to meet on November 15 and hold a discussion on intranasal

Bharat Biotech has applied for market authorisation from the Drugs Controller General of India (DCGI) for intranasal heterologous booster, sources told ANI.